Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

NCT03263429 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Metastatic Colorectal Cancer
RAS Wild Type Colorectal Cancer
Refractory Colorectal Cancer

Interventions

DRUG: Glutaminase Inhibitor CB-839
BIOLOGICAL: Panitumumab
DRUG: Irinotecan Hydrochloride (phase I only)
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DEVICE: Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]
[object Object]